Want to see HK:3347 full AI Analyst Report?
3347 Stock Chart & Stats
HK$54.00
HK$0.35(1.23%)
At close: 4:00 PM EST
HK$54.00
HK$0.35(1.23%)
Day’s Range― - ―
52-Week RangeHK$28.12 - HK$57.00
Previous CloseN/A
Volume678.40K
Average Volume (3M)1.84M
Market Cap
HK$50.49B
Enterprise ValueHK$33.48K
Total Cash (Recent Filing)HK$2.15B
Total Debt (Recent Filing)HK$2.35B
Price to Earnings (P/E)710.1
Beta1.74
Next Earnings
Oct 22, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend Yield0.32%
Share Statistics
EPS (TTM)0.10
Shares Outstanding123,124,800
10 Day Avg. Volume1,606,844
30 Day Avg. Volume1,841,259
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)1.57
Price to Sales (P/S)4.81
P/FCF Ratio36.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$52.42Price Target Upside-2.93% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.69
Revenue Forecast (FY)HK$9.00B
Bulls Say, Bears Say
Bulls Say
Low Leverage And Strong Equity BaseConservative leverage and a substantial equity base provide financial resilience through business cycles. Tigermed has flexibility to fund operations, absorb weaker periods, and pursue development without relying heavily on debt or facing elevated balance-sheet strain.
Strong Positive Free Cash FlowSustained positive cash generation gives the CRO a durable source of internal funding for operations, investment, and shareholder returns. Strong free-cash-flow growth and healthy conversion relative to earnings indicate that reported performance is substantially supported by cash.
CRO Model Serves A Broad Development MarketTigermed participates in outsourced drug and device development, serving multiple customer types and geographies. This business model can support durable demand because clients require clinical execution, regulatory support, and research capabilities across therapeutic programs.
Bears Say
Material Profitability CompressionThe sharp decline in gross and net margins shows that recent revenue activity has translated into substantially less profit than in prior years. Unless margins recover, weaker operating leverage could limit earnings growth and reduce the long-term returns generated from the company’s asset base.
Sharp Decline In Net Income And EPSThe steep earnings deterioration indicates that profitability is currently less consistent and less powerful than before. Persistently lower earnings would constrain reinvestment capacity, weaken return metrics, and make future growth more dependent on restoring operating performance rather than simply expanding revenue.
Operating Cash-flow Coverage VolatilityAlthough free cash flow remains positive, relatively low and inconsistent operating-cash-flow coverage versus reported profitability suggests that cash realization may fluctuate with working capital or project timing. This can make funding visibility and earnings quality less predictable over the next several quarters.
Hangzhou Tigermed Consulting Co., Ltd. Class H News
3347 FAQ
What was Hangzhou Tigermed Consulting Co., Ltd. Class H’s price range in the past 12 months?
Hangzhou Tigermed Consulting Co., Ltd. Class H lowest stock price was HK$28.12 and its highest was HK$57.00 in the past 12 months.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap is HK$50.49B.
When is Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date is Oct 22, 2026 which is in 25 days.
How were Hangzhou Tigermed Consulting Co., Ltd. Class H’s earnings last quarter?
Hangzhou Tigermed Consulting Co., Ltd. Class H released its earnings results on Aug 28, 2026. The company reported -HK$0.626 earnings per share for the quarter, missing the consensus estimate of HK$0.249 by -HK$0.875.
Is Hangzhou Tigermed Consulting Co., Ltd. Class H overvalued?
According to Wall Street analysts Hangzhou Tigermed Consulting Co., Ltd. Class H’s price is currently Overvalued.
Does Hangzhou Tigermed Consulting Co., Ltd. Class H pay dividends?
Hangzhou Tigermed Consulting Co., Ltd. Class H pays a Annually dividend of HK$0.145 which represents an annual dividend yield of 0.32%. See more information on Hangzhou Tigermed Consulting Co., Ltd. Class H dividends here
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate is 0.38.
How many shares outstanding does Hangzhou Tigermed Consulting Co., Ltd. Class H have?
Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding.
What happened to Hangzhou Tigermed Consulting Co., Ltd. Class H’s price movement after its last earnings report?
Hangzhou Tigermed Consulting Co., Ltd. Class H reported an EPS of -HK$0.626 in its last earnings report, missing expectations of HK$0.249. Following the earnings report the stock price went down -3.729%.
Which hedge fund is a major shareholder of Hangzhou Tigermed Consulting Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3347
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hangzhou Tigermed Consulting Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$52.42 (-2.93% Downside)
HK$52.42 (-2.93% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
0.32%
Trailing 12-Months
Asset Growth
6.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
3347 Stock 12 Month Forecast
Average Price Target
HK$52.42
▼(-2.93% Downside)
Technical Analysis
WuXi AppTec Co., Ltd. Class H
―
JOINN Laboratories (China) Co., Ltd. Class H
―
Mega Genomics Limited
―
ADICON Holdings Limited
―
WuXi XDC Cayman, Inc.
―